Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28353554 | 0.90 | EPHX2 (0.39) | MDM4TP53EPHX2PRCPCASP3 | |
| SCHEMBL29555021 | 0.90 | EPHX2 (0.39) | MDM4TP53EPHX2PRCPCASP3 | |
| SCHEMBL29555034 | 0.89 | EPHX2 (0.38) | MDM4TP53EPHX2PRCPCASP3 | |
| SCHEMBL30421774 | 0.87 | MDM4 (0.54) | MDM4TP53CASP3MDM2 | |
| SCHEMBL26976628 | 0.87 | MDM4 (0.54) | MDM4TP53CASP3MDM2 | |
| SCHEMBL26976589 | 0.87 | MDM4 (0.54) | MDM4TP53CASP3MDM2 | |
| SCHEMBL29824847 | 0.80 | MDM4 (0.48) | MDM4TP53EPHX2CASP3KMT2A | |
| SCHEMBL3421848 | 0.80 | MDM4 (0.48) | MDM4TP53EPHX2CASP3KMT2A | |
| SCHEMBL31000608 | 0.80 | MDM4 (0.48) | MDM4TP53EPHX2CASP3KMT2A | |
| SCHEMBL28215462 | 0.80 | MDM4 (0.48) | MDM4TP53EPHX2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858905-B1 | Cathepsin L inhibitors | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858905-B1 | Cathepsin L inhibitors | CTSV, CTSL, CTSB | MDM4 4028/4885TP53 785/4885EPHX2 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.